PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRadium ra-223
Radium ra-223
Radium ra-223 is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V10: Therapeutic radiopharmaceuticals
— V10X: Other therapeutic radiopharmaceuticals in atc
— V10XX: Various therapeutic radiopharmaceuticals
— V10XX03: Radium (223ra) dichloride
HCPCS
Code
Description
A9606
Radium ra-223 dichloride, therapeutic, per microcurie
Clinical
Clinical Trials
118 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471—C611028622365
Neoplasm metastasisD009362EFO_0009708—22—1—5
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Castration-resistant prostatic neoplasmsD064129——1092—1733
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD000230——23——15
Breast neoplasmsD001943EFO_0003869C50—5———5
Bone neoplasmsD001859EFO_0003820D1612——14
NeoplasmsD009369—C8021——13
Renal cell carcinomaD002292EFO_0000376—22———3
Multiple myelomaD009101—C90.022———2
Triple negative breast neoplasmsD064726———1———1
Thyroid neoplasmsD013964EFO_0003841——1———1
Small cell lung carcinomaD055752———1———1
PainD010146EFO_0003843R52—1———1
Show 1 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urologic neoplasmsD014571—C64-C681————1
Non-small-cell lung carcinomaD002289——1————1
Bone diseasesD001847—M89.91————1
PharmacokineticsD010599——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRadium ra-223
INN—
Description
Radium-223 (223Ra, Ra-223) is an isotope of radium with an 11.4-day half-life. It was discovered in 1905 by T. Godlewski, a Polish chemist from Kraków, and was historically known as actinium X (AcX). Radium-223 dichloride is an alpha particle-emitting radiotherapy drug that mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover. The principal use of radium-223, as a radiopharmaceutical to treat metastatic cancers in bone, takes advantage of its chemical similarity to calcium, and the short range of the alpha radiation it emits.
Classification
Small molecule
Drug classquaternary ammonium derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
[223Ra]
Identifiers
PDB—
CAS-ID15623-45-7
RxCUI—
ChEMBL IDCHEMBL4297420
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 57 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,626 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use